Thrombelastography-Based Dosing of Enoxaparin for Thromboprophylaxis in Trauma and Surgical Patients: A Randomized Clinical Trial

IMPORTANCE: Prophylactic enoxaparin is used to prevent venous thromboembolism (VTE) in surgical and trauma patients. However, VTE remains an important source of morbidity and mortality, potentially exacerbated by antithrombin III or anti–Factor Xa deficiencies and missed enoxaparin doses. Recent dat...

Full description

Saved in:
Bibliographic Details
Published inJAMA surgery Vol. 151; no. 10; p. e162069
Main Authors Connelly, Christopher R, Van, Philbert Y, Hart, Kyle D, Louis, Scott G, Fair, Kelly A, Erickson, Anfin S, Rick, Elizabeth A, Simeon, Erika C, Bulger, Eileen M, Arbabi, Saman, Holcomb, John B, Moore, Laura J, Schreiber, Martin A
Format Journal Article
LanguageEnglish
Published United States American Medical Association 19.10.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract IMPORTANCE: Prophylactic enoxaparin is used to prevent venous thromboembolism (VTE) in surgical and trauma patients. However, VTE remains an important source of morbidity and mortality, potentially exacerbated by antithrombin III or anti–Factor Xa deficiencies and missed enoxaparin doses. Recent data suggest that a difference in reaction time (time to initial fibrin formation) greater than 1 minute between heparinase and standard thrombelastogram (TEG) is associated with a decreased risk of VTE. OBJECTIVE: To evaluate the effectiveness of TEG-adjusted prophylactic enoxaparin dosing among trauma and surgical patients. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial, conducted from October 2012 to May 2015, compared standard dosing (30 mg twice daily) with TEG-adjusted enoxaparin dosing (35 mg twice daily) for 185 surgical and trauma patients screened for VTE at 3 level I trauma centers in the United States. MAIN OUTCOMES AND MEASURES: The incidence of VTE, bleeding complications, anti–Factor Xa deficiency, and antithrombin III deficiency. RESULTS: Of the 185 trial participants, 89 were randomized to the control group (median age, 44.0 years; 55.1% male) and 96 to the intervention group (median age, 48.5 years; 74.0% male). Patients in the intervention group received a higher median enoxaparin dose than control patients (35 mg vs 30 mg twice daily; P < .001). Anti–Factor Xa levels in intervention patients were not higher than levels in control patients until day 6 (0.4 U/mL vs 0.21 U/mL; P < .001). Only 22 patients (11.9%) achieved a difference in reaction time greater than 1 minute, which was similar between the control and intervention groups (10.4% vs 13.5%; P = .68). The time to enoxaparin initiation was similar between the control and intervention groups (median [range] days, 1.0 [0.0-2.0] vs 1.0 [1.0-2.0]; P = .39), and the number of patients who missed at least 1 dose was also similar (43 [48.3%] vs 54 [56.3%]; P = .30). Rates of VTE (6 [6.7%] vs 6 [6.3%]; P > .99) were similar, but the difference in bleeding complications (5 [5.6%] vs 13 [13.5%]; P = .08) was not statistically significant. Antithrombin III and anti–Factor Xa deficiencies and hypercoaguable TEG parameters, including elevated coagulation index (>3), maximum amplitude (>74 mm), and G value (>12.4 dynes/cm2), were prevalent in both groups. Identified risk factors for VTE included older age (61.0 years vs 46.0 years; P = .04), higher body mass index (calculated as weight in kilograms divided by height in meters squared; 30.6 vs 27.1; P = .03), increased Acute Physiology and Chronic Health Evaluation II score (8.5 vs 7.0; P = .03), and increased percentage of missed doses per patient (14.8% vs 2.5%; P = .05). CONCLUSIONS AND RELEVANCE: The incidence of VTE was low and similar between groups; however, few patients achieved a difference in reaction time greater than 1 minute. Antithrombin III deficiencies and hypercoaguable TEG parameters were prevalent among patients with VTE. Low VTE incidence may be due to an early time to enoxaparin initiation and an overall healthier and less severely injured study population than previously reported. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00990236.
AbstractList Prophylactic enoxaparin is used to prevent venous thromboembolism (VTE) in surgical and trauma patients. However, VTE remains an important source of morbidity and mortality, potentially exacerbated by antithrombin III or anti-Factor Xa deficiencies and missed enoxaparin doses. Recent data suggest that a difference in reaction time (time to initial fibrin formation) greater than 1 minute between heparinase and standard thrombelastogram (TEG) is associated with a decreased risk of VTE. To evaluate the effectiveness of TEG-adjusted prophylactic enoxaparin dosing among trauma and surgical patients. This randomized clinical trial, conducted from October 2012 to May 2015, compared standard dosing (30 mg twice daily) with TEG-adjusted enoxaparin dosing (35 mg twice daily) for 185 surgical and trauma patients screened for VTE at 3 level I trauma centers in the United States. The incidence of VTE, bleeding complications, anti-Factor Xa deficiency, and antithrombin III deficiency. Of the 185 trial participants, 89 were randomized to the control group (median age, 44.0 years; 55.1% male) and 96 to the intervention group (median age, 48.5 years; 74.0% male). Patients in the intervention group received a higher median enoxaparin dose than control patients (35 mg vs 30 mg twice daily; P < .001). Anti-Factor Xa levels in intervention patients were not higher than levels in control patients until day 6 (0.4 U/mL vs 0.21 U/mL; P < .001). Only 22 patients (11.9%) achieved a difference in reaction time greater than 1 minute, which was similar between the control and intervention groups (10.4% vs 13.5%; P = .68). The time to enoxaparin initiation was similar between the control and intervention groups (median [range] days, 1.0 [0.0-2.0] vs 1.0 [1.0-2.0]; P = .39), and the number of patients who missed at least 1 dose was also similar (43 [48.3%] vs 54 [56.3%]; P = .30). Rates of VTE (6 [6.7%] vs 6 [6.3%]; P > .99) were similar, but the difference in bleeding complications (5 [5.6%] vs 13 [13.5%]; P = .08) was not statistically significant. Antithrombin III and anti-Factor Xa deficiencies and hypercoagulable TEG parameters, including elevated coagulation index (>3), maximum amplitude (>74 mm), and G value (>12.4 dynes/cm2), were prevalent in both groups. Identified risk factors for VTE included older age (61.0 years vs 46.0 years; P = .04), higher body mass index (calculated as weight in kilograms divided by height in meters squared; 30.6 vs 27.1; P = .03), increased Acute Physiology and Chronic Health Evaluation II score (8.5 vs 7.0; P = .03), and increased percentage of missed doses per patient (14.8% vs 2.5%; P = .05). The incidence of VTE was low and similar between groups; however, few patients achieved a difference in reaction time greater than 1 minute. Antithrombin III deficiencies and hypercoagulable TEG parameters were prevalent among patients with VTE. Low VTE incidence may be due to an early time to enoxaparin initiation and an overall healthier and less severely injured study population than previously reported. clinicaltrials.gov Identifier: NCT00990236.
IMPORTANCE: Prophylactic enoxaparin is used to prevent venous thromboembolism (VTE) in surgical and trauma patients. However, VTE remains an important source of morbidity and mortality, potentially exacerbated by antithrombin III or anti–Factor Xa deficiencies and missed enoxaparin doses. Recent data suggest that a difference in reaction time (time to initial fibrin formation) greater than 1 minute between heparinase and standard thrombelastogram (TEG) is associated with a decreased risk of VTE. OBJECTIVE: To evaluate the effectiveness of TEG-adjusted prophylactic enoxaparin dosing among trauma and surgical patients. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial, conducted from October 2012 to May 2015, compared standard dosing (30 mg twice daily) with TEG-adjusted enoxaparin dosing (35 mg twice daily) for 185 surgical and trauma patients screened for VTE at 3 level I trauma centers in the United States. MAIN OUTCOMES AND MEASURES: The incidence of VTE, bleeding complications, anti–Factor Xa deficiency, and antithrombin III deficiency. RESULTS: Of the 185 trial participants, 89 were randomized to the control group (median age, 44.0 years; 55.1% male) and 96 to the intervention group (median age, 48.5 years; 74.0% male). Patients in the intervention group received a higher median enoxaparin dose than control patients (35 mg vs 30 mg twice daily; P < .001). Anti–Factor Xa levels in intervention patients were not higher than levels in control patients until day 6 (0.4 U/mL vs 0.21 U/mL; P < .001). Only 22 patients (11.9%) achieved a difference in reaction time greater than 1 minute, which was similar between the control and intervention groups (10.4% vs 13.5%; P = .68). The time to enoxaparin initiation was similar between the control and intervention groups (median [range] days, 1.0 [0.0-2.0] vs 1.0 [1.0-2.0]; P = .39), and the number of patients who missed at least 1 dose was also similar (43 [48.3%] vs 54 [56.3%]; P = .30). Rates of VTE (6 [6.7%] vs 6 [6.3%]; P > .99) were similar, but the difference in bleeding complications (5 [5.6%] vs 13 [13.5%]; P = .08) was not statistically significant. Antithrombin III and anti–Factor Xa deficiencies and hypercoaguable TEG parameters, including elevated coagulation index (>3), maximum amplitude (>74 mm), and G value (>12.4 dynes/cm2), were prevalent in both groups. Identified risk factors for VTE included older age (61.0 years vs 46.0 years; P = .04), higher body mass index (calculated as weight in kilograms divided by height in meters squared; 30.6 vs 27.1; P = .03), increased Acute Physiology and Chronic Health Evaluation II score (8.5 vs 7.0; P = .03), and increased percentage of missed doses per patient (14.8% vs 2.5%; P = .05). CONCLUSIONS AND RELEVANCE: The incidence of VTE was low and similar between groups; however, few patients achieved a difference in reaction time greater than 1 minute. Antithrombin III deficiencies and hypercoaguable TEG parameters were prevalent among patients with VTE. Low VTE incidence may be due to an early time to enoxaparin initiation and an overall healthier and less severely injured study population than previously reported. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00990236.
ImportanceProphylactic enoxaparin is used to prevent venous thromboembolism (VTE) in surgical and trauma patients. However, VTE remains an important source of morbidity and mortality, potentially exacerbated by antithrombin III or anti-Factor Xa deficiencies and missed enoxaparin doses. Recent data suggest that a difference in reaction time (time to initial fibrin formation) greater than 1 minute between heparinase and standard thrombelastogram (TEG) is associated with a decreased risk of VTE.ObjectiveTo evaluate the effectiveness of TEG-adjusted prophylactic enoxaparin dosing among trauma and surgical patients.Design, Setting, and ParticipantsThis randomized clinical trial, conducted from October 2012 to May 2015, compared standard dosing (30 mg twice daily) with TEG-adjusted enoxaparin dosing (35 mg twice daily) for 185 surgical and trauma patients screened for VTE at 3 level I trauma centers in the United States.Main Outcomes and MeasuresThe incidence of VTE, bleeding complications, anti-Factor Xa deficiency, and antithrombin III deficiency.ResultsOf the 185 trial participants, 89 were randomized to the control group (median age, 44.0 years; 55.1% male) and 96 to the intervention group (median age, 48.5 years; 74.0% male). Patients in the intervention group received a higher median enoxaparin dose than control patients (35 mg vs 30 mg twice daily; P < .001). Anti-Factor Xa levels in intervention patients were not higher than levels in control patients until day 6 (0.4 U/mL vs 0.21 U/mL; P < .001). Only 22 patients (11.9%) achieved a difference in reaction time greater than 1 minute, which was similar between the control and intervention groups (10.4% vs 13.5%; P = .68). The time to enoxaparin initiation was similar between the control and intervention groups (median [range] days, 1.0 [0.0-2.0] vs 1.0 [1.0-2.0]; P = .39), and the number of patients who missed at least 1 dose was also similar (43 [48.3%] vs 54 [56.3%]; P = .30). Rates of VTE (6 [6.7%] vs 6 [6.3%]; P > .99) were similar, but the difference in bleeding complications (5 [5.6%] vs 13 [13.5%]; P = .08) was not statistically significant. Antithrombin III and anti-Factor Xa deficiencies and hypercoagulable TEG parameters, including elevated coagulation index (>3), maximum amplitude (>74 mm), and G value (>12.4 dynes/cm2), were prevalent in both groups. Identified risk factors for VTE included older age (61.0 years vs 46.0 years; P = .04), higher body mass index (calculated as weight in kilograms divided by height in meters squared; 30.6 vs 27.1; P = .03), increased Acute Physiology and Chronic Health Evaluation II score (8.5 vs 7.0; P = .03), and increased percentage of missed doses per patient (14.8% vs 2.5%; P = .05).Conclusions and RelevanceThe incidence of VTE was low and similar between groups; however, few patients achieved a difference in reaction time greater than 1 minute. Antithrombin III deficiencies and hypercoagulable TEG parameters were prevalent among patients with VTE. Low VTE incidence may be due to an early time to enoxaparin initiation and an overall healthier and less severely injured study population than previously reported.Trial Registrationclinicaltrials.gov Identifier: NCT00990236.
Author Erickson, Anfin S
Louis, Scott G
Rick, Elizabeth A
Connelly, Christopher R
Holcomb, John B
Moore, Laura J
Bulger, Eileen M
Van, Philbert Y
Fair, Kelly A
Simeon, Erika C
Arbabi, Saman
Hart, Kyle D
Schreiber, Martin A
Author_xml – sequence: 1
  givenname: Christopher R
  surname: Connelly
  fullname: Connelly, Christopher R
– sequence: 2
  givenname: Philbert Y
  surname: Van
  fullname: Van, Philbert Y
– sequence: 3
  givenname: Kyle D
  surname: Hart
  fullname: Hart, Kyle D
– sequence: 4
  givenname: Scott G
  surname: Louis
  fullname: Louis, Scott G
– sequence: 5
  givenname: Kelly A
  surname: Fair
  fullname: Fair, Kelly A
– sequence: 6
  givenname: Anfin S
  surname: Erickson
  fullname: Erickson, Anfin S
– sequence: 7
  givenname: Elizabeth A
  surname: Rick
  fullname: Rick, Elizabeth A
– sequence: 8
  givenname: Erika C
  surname: Simeon
  fullname: Simeon, Erika C
– sequence: 9
  givenname: Eileen M
  surname: Bulger
  fullname: Bulger, Eileen M
– sequence: 10
  givenname: Saman
  surname: Arbabi
  fullname: Arbabi, Saman
– sequence: 11
  givenname: John B
  surname: Holcomb
  fullname: Holcomb, John B
– sequence: 12
  givenname: Laura J
  surname: Moore
  fullname: Moore, Laura J
– sequence: 13
  givenname: Martin A
  surname: Schreiber
  fullname: Schreiber, Martin A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27487253$$D View this record in MEDLINE/PubMed
BookMark eNpFkMtOGzEUhi0EAkp5gSyQl2wGfLeHHaRpi4QEasN6dGbiSYxm7GDPSKQ73hyn4XIWPpb-i46-b2jfB28RmlByQQmhl0_QQxrj8oIRqvKjyj10zKgyhWKK7X_-pThCpyk9kTyGEMHLQ3TEtDCaSX6MXuerGPradpCGsIywXm2KG0h2gX-E5PwShxbPfHiBNUTncRsi3iXCOoZs7uDFJZyVeYSxBwx-gf_ms1wDHX6AwVk_pCt8jf9kJfTuX26eds7_1-fRQfcdHbTQJXv6vk_Q48_ZfPq7uLv_dTu9viuAaT4UopbUiBoWWihRypLWplZaM2Cm0VzwxuiGKVvbllgjGmZKbXnbWikN41TW_ASd73rz4c-jTUPVu9TYrgNvw5gqapjSgkqls5XtrE0MKUXbVuvoeoibipJqS7_6oF9t6Vdb-jl09t4_1r1dfEY-WGfDZGfI2S9Vci2V4G8vno34
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1001/jamasurg.2016.2069
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 2168-6262
EndPage e162069
ExternalDocumentID 10_1001_jamasurg_2016_2069
27487253
2537564
Genre Research Support, U.S. Gov't, Non-P.H.S
Multicenter Study
Randomized Controlled Trial
Journal Article
GroupedDBID 0R~
4.4
AAWTL
ABBLC
ABJNI
ACDNT
ACGFS
ADBBV
AENEX
AHMBA
ALMA_UNASSIGNED_HOLDINGS
AMJDE
ANMPU
BRYMA
C45
EBD
EBS
EJD
EMOBN
EX3
GX1
OB2
OBH
OHH
OVD
PQQKQ
RAJ
SV3
TEORI
WOW
CGR
CUY
CVF
ECM
EIF
H13
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-a273t-4b5184bad74649591b8b6772a28c7343c87c26ebef0e84c2897e3ffe5582315b3
ISSN 2168-6254
IngestDate Tue Aug 27 04:48:21 EDT 2024
Fri Aug 23 03:00:25 EDT 2024
Sat Sep 28 08:48:08 EDT 2024
Fri Jul 05 02:03:52 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-a273t-4b5184bad74649591b8b6772a28c7343c87c26ebef0e84c2897e3ffe5582315b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
PMID 27487253
PQID 1826741567
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1826741567
crossref_primary_10_1001_jamasurg_2016_2069
pubmed_primary_27487253
ama_primary_2537564
PublicationCentury 2000
PublicationDate 2016-10-19
PublicationDateYYYYMMDD 2016-10-19
PublicationDate_xml – month: 10
  year: 2016
  text: 2016-10-19
  day: 19
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle JAMA surgery
PublicationTitleAlternate JAMA Surg
PublicationYear 2016
Publisher American Medical Association
Publisher_xml – name: American Medical Association
References 27486696 - JAMA Surg. 2016 Oct 19;151(10 ):e162081
References_xml
SSID ssj0000800439
Score 2.4789689
Snippet IMPORTANCE: Prophylactic enoxaparin is used to prevent venous thromboembolism (VTE) in surgical and trauma patients. However, VTE remains an important source...
Prophylactic enoxaparin is used to prevent venous thromboembolism (VTE) in surgical and trauma patients. However, VTE remains an important source of morbidity...
ImportanceProphylactic enoxaparin is used to prevent venous thromboembolism (VTE) in surgical and trauma patients. However, VTE remains an important source of...
SourceID proquest
crossref
pubmed
ama
SourceType Aggregation Database
Index Database
Publisher
StartPage e162069
SubjectTerms Adult
Anticoagulants - administration & dosage
Drug Administration Schedule
Enoxaparin - administration & dosage
Female
Humans
Male
Middle Aged
Prospective Studies
Thrombelastography
Trauma Centers
Treatment Outcome
United States
Venous Thromboembolism - prevention & control
Title Thrombelastography-Based Dosing of Enoxaparin for Thromboprophylaxis in Trauma and Surgical Patients: A Randomized Clinical Trial
URI http://dx.doi.org/10.1001/jamasurg.2016.2069
https://www.ncbi.nlm.nih.gov/pubmed/27487253
https://search.proquest.com/docview/1826741567
Volume 151
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ja9wwFBbT9NJL6d7phgq9GQ9jW4t97JImdKO0SZmejGTLEEjsMmND0l_fT5a3STrQ9GIGWSPZep_eIr-FkFeF4blggfIhPAqfRVniJ1HG_cKYKFSRKGQbHv35izg8Zh9WfDWbTb2Wmlovst9_jSv5H6qiDXS1UbLXoOwwKBrwG_TFFRTG9R9pvK7OtIECXHeZp_03kEo51OJN5828X1bnylYadA6F7h8V2CY6n6rzk9YdFgKrOVPOi7NZO1741SVc3Wxpr-DQ3mYSSN3Gd7SeMheXMhV43xZ9jx_ujNUe3Vgvbu_nYmR7LmDo48Wp8d4NzZ-qxmU--N4mjjhYTI8mAmF5escAWw4WBiL2YWCxLXbbJZjtcLWccE8TiHDpKrdc4exjRQH7mtYnzzqYuM7babQvibfB6dAlaIa5042R2jFSO8YNcjOUCbceoQerYDiis8o0a2vRDS_ShV31eau2H2WarLdXcHZYLa32cnSH3O7MDvraYegumZnyPsl34Yc6_NCqoCN-KPBDr-KH4o7DDwV-aI8f2uPnATl-v3_09tDvqm74Cqps7TPNYfVrlUsmYD0ngY61gA2mwjiTEXZzLLNQYO8XSxOzDAa7NFGBPc_tF2Wuo4dkr6xK85jQXEI66Ezl3BhbpiEJtYjjImNGaAi2ZE7uYcHSXy6vShrySHLB5sTrF3C4tZt2c_KyX-MUnNF-7lKlqZpNai1nqy8LOSeP3OKPU0kY6pjvybXmekpujTB_RvbqdWOeQyet9YsWOX8ArsON8A
link.rule.ids 315,786,790,27955,27956
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thrombelastography-Based+Dosing+of+Enoxaparin+for+Thromboprophylaxis+in+Trauma+and+Surgical+Patients&rft.jtitle=JAMA+surgery&rft.au=Connelly%2C+Christopher+R.&rft.au=Van%2C+Philbert+Y.&rft.au=Hart%2C+Kyle+D.&rft.au=Louis%2C+Scott+G.&rft.date=2016-10-19&rft.issn=2168-6254&rft.volume=151&rft.issue=10&rft.spage=e162069&rft_id=info:doi/10.1001%2Fjamasurg.2016.2069&rft.externalDBID=n%2Fa&rft.externalDocID=10_1001_jamasurg_2016_2069
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2168-6254&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2168-6254&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2168-6254&client=summon